BKYI vs CJMB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BKYI exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile stability, and lacks an Altman Z-Score, raising unquantified distress risk. The company reports severe profitability issues, including a -67.34% profit margin, -137.69% ROE, and negative earnings across all recent quarters, despite a high gross margin of 78.40%. Revenue has declined 27.7% YoY, and earnings surprises have been consistently negative in the last four quarters, with an average miss of -17.33%. The stock trades at a price-to-book of 0.80, but this is misleading given the company’s deep losses and negative equity. Analysts have a target price of $2.00, but with only one analyst covering the stock and no consensus, this is not reliable.
CJMB shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BKYI vs CJMB: Head-to-Head Comparison
This page compares BIO-key International, Inc. (BKYI) and Callan JMB Inc. (CJMB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.